This raises the question of whether SGLT2 inhibitors are associated not only with a reduced risk of cardiovascular disease, but also with a reduced risk of inner ear disorders such as sensorineural hearing loss or tinnitus. This evidence concerns the gene SLC5A2 and sensorineural hearing loss disorder.